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Mark Tanner, Robin Tyacke, Kim Wolff, Ajun Sethi, Michael A.P. Bloomﬁeld, Tim M. Williams,
Mark Bolstridge, Lorna Stewart, Celia Morgan, Rexford D. Newbould, Amanda Feilding, H. Val Curran,
and David J. NuttBackground: The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute
euphoria in most individuals.
Methods: In a double-blind, placebo-controlled, balanced-order study, MDMA was orally administered to 25 physically and mentally
healthy individuals. Arterial spin labeling and seed-based resting state functional connectivity (RSFC) were used to produce spatial maps
displaying changes in cerebral blood ﬂow (CBF) and RSFC after MDMA administration. Participants underwent two arterial spin labeling
and two blood oxygen level–dependent scans in a 90-minute scan session; MDMA and placebo study days were separated by 1 week.
Results: Marked increases in positive mood were produced by MDMA. Decreased CBF only was observed after MDMA, and this was
localized to the right medial temporal lobe (MTL), thalamus, inferior visual cortex, and the somatosensory cortex. Decreased CBF in the
right amygdala and hippocampus correlated with ratings of the intensity of global subjective effects of MDMA. The RSFC results
complemented the CBF results, with decreases in RSFC between midline cortical regions, the medial prefrontal cortex, and MTL regions,
and increases between the amygdala and hippocampus. There were trend-level correlations between these effects and ratings of intense
and positive subjective effects.
Conclusions: The MTLs appear to be speciﬁcally implicated in the mechanism of action of MDMA, but further work is required to
elucidate how the drug’s characteristic subjective effects arise from its modulation of spontaneous brain activity.Key Words: Amygdala, 5-HT, fMRI, hippocampus, MDMA, PTSD,
serotoninThe compound 3,4-methylenedioxymethamphetamine (MDMA)releases serotonin (5-hydroxytryptamine [5-HT]), dopamine,and norepinephrine (1). It is also a popular recreational drug
that is valued by users because of its acute prosocial and euphoretic
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http://dx.doi.org/10.1016/j.biopsych.2013.12.015research on numerous occasions (3–5), few studies have inves-
tigated its acute effects on brain function using functional magnetic
resonance imaging (fMRI) (6–8) or other neuroimaging modalities
(9–11).
The compound MDMA has a relatively unique proﬁle of
subjective effects, described as a hybrid between a stimulant
and psychedelic (12). It acts at dopamine, norepinephrine, and
5-HT transporters to inhibit reuptake and stimulate release;
however, the greater action of MDMA at the serotonin transporter
differentiates it from most other stimulants (13) and accounts for
much, but not all, of its euphoretic effects (14,15). Although the
pharmacology of MDMA is reasonably well understood, little is
known about its effects on global brain function. More recently,
MDMA has been investigated as a potential adjunct to psycho-
therapy in the treatment of posttraumatic stress disorder (PTSD),
with positive, albeit preliminary, outcomes (16,17).
Despite signiﬁcant developments in resting state fMRI in
recent years (18), there have been no resting state fMRI studies
on the acute effects of MDMA. In the present study, we combined
arterial spin labeling (ASL) and resting state functional connec-
tivity (RSFC) to address this knowledge gap. The magnetic
resonance imaging technique ASL provides a quantitative meas-
ure of cerebral blood ﬂow (CBF) or perfusion (19), and RSFC
measures functional coupling between spatially distributed brain
regions via spontaneous ﬂuctuations in the blood oxygen level–BIOL PSYCHIATRY 2014;]:]]]–]]]
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techniques can yield important new information on how a drug
alters brain activity to produce its characteristic subjective effects
(21). Given the recognized acute prosocial and positive mood
effects of MDMA (6,22), we predicted changes in CBF and RSFC in
brain systems implicated in social and affective processing—
limbic structures and the medial prefrontal cortex (mPFC) (23,24).
On this basis, three regions (i.e., ventromedial prefrontal cortex
[vmPFC], bilateral hippocampi, and amygdalae) were selected for
seed-based RSFC analyses (20).
Supporting the importance of this research is: 1) the relative
dearth of human functional neuroimaging data on what is one of
the most popular drugs of potential misuse (25); 2) the ability of
MDMA to produce an acute state of euphoria and the poor
understanding of the neural underpinnings of such states (26); 3)
the ability of MDMA to produce marked 5-HT release (13), support-
ing its utility in serotoninergic challenge (27); and 4) preliminary
evidence for the potential of MDMA as a therapeutic agent (17).
Methods and Materials
Supplement 1 contains the complete Methods and Materials
section.
Design
This was a within-subjects, double-blind, randomized, placebo-
controlled study. Participants were scanned twice, 7 days apart—
once after MDMA and once after placebo. A schematic of the
scanning protocol is shown in Figure 1. The study was approved by
the National Research Ethics Service West London Research Ethics
Committee, Joint Compliance and Research Ofﬁce of Imperial
College London, Research Ethics Committee of Imperial College
London, Head of the Department of Medicine of Imperial College
London, Imanova Centre for Imaging Science, and Faculty of
Medicine of Imperial College London. The study was conducted
in accordance with Good Clinical Practice guidelines. A Home
Ofﬁce Licence was obtained for the storage and handling of a
Schedule 1 drug. Imperial College London sponsored the research.
Participants
The study included 25 healthy participants (mean age, 34  11
years; 7 females) with at least one previous experience with
MDMA. None of the participants had used MDMA for at least 7
days or other drugs for at least 48 hours, which was conﬁrmed by
a urine screen. An alcohol breathalyzer test conﬁrmed that none of
the participants had recently consumed alcohol. Participants had
used MDMA an average of 35  51 times before (range, 1–200
times), and the mean time since last use was 1400  2351 days
(range, 7–7300 days). Participants were screened for good physical
and mental health, and magnetic resonance imaging compatibil-
ity. Screening involved routine blood tests, electrocardiogram,
heart rate, blood pressure, and a brief neurologic examination. Thewww.sobp.org/journalMini International Neuropsychiatric Interview version 5 (MINI-5)
was performed by an experienced psychiatrist to assess mental
health. All subjects were deemed physically and mentally healthy,
and none had any history of drug or alcohol dependence or
diagnosed psychiatric disorder. Participants had mean Beck
Depression Inventory scores of 3.9  4.8 (range, 0–18) and
Spielberger State-Trait Anxiety Inventory scores of 31.7  5.9
(range, 20–46).Results
Basic Subjective and Physiologic Effects
The intensity of the subjective effects of MDMA was variable
across subjects. Five subjects failed to notice any subjective effects
during the scanning period, whereas three gave maximal ratings,
indicating “extremely intense” effects. Peak drug effects were
reported 100 min after ingestion of MDMA (the intensity was rated
at 52  32%; range, 0%–100%; 0% ¼ no effects and 100% ¼
extremely intense effects) coinciding with the beginning of the
second ASL scan (103 min after capsule ingestion). However, the
average intensity remained relatively consistent throughout the
scanning period (i.e., intensity was rated at 44 35% at the end of
the ﬁrst ASL scan and 43  32% at the end of the second BOLD
scan). Most volunteers reported positive mood effects after
MDMA, and items referring to aspects of positive mood were
among the highest scored (e.g., the item “I felt amazing” was the
highest rated item after MDMA administration) (Figure 2).
Mean Plasma Concentration of MDMA
Biochip Array Technology (Randox Laboratories Ltd., Co.,
Antrim, United Kingdom) was used to detect MDMA from plasma
samples obtained shortly after each participant’s MDMA scanning
session (i.e., 2 hours after capsule ingestion). The mean concen-
tration of MDMA was 214  66 ng/mL.
ASL Results
Subtracting the two ASL scans after MDMA administration
from the two ASL scans after placebo revealed robust decreases
in CBF after MDMA. The images shown in Figure 3A were
produced using cluster-correction (2590 voxels) to adjust for
multiple comparisons and a whole-brain corrected statistical
threshold of p  .05. At this threshold, decreases in CBF only
were observed, and these were localized to the regions shown in
Figure 3A. Increases in CBF could be observed only at an
unacceptable statistical threshold of puncorrected  .3. For a more
comprehensive display of the regional decreases in CBF after
MDMA, see Supplement 1.
When contrasts were split so that the effect of MDMA in
the ﬁrst and second ASL scans could be observed sepa-
rately, consistent maps were revealed, with decreases in CBF
only after MDMA. The decreases were slightly more marked andFigure 1. Schematic showing scanning protocol. Pla-
cebo (vitamin C) or 3,4-methylenedioxymethampheta-
mine (MDMA) hydrochloride (100 mg) was ingested at
time zero, and the ﬁrst arterial spin labeling scan
performed 50 min later. This was a repeated measures
design; the two scans (placebo and MDMA) were
performed 1 week apart, and the scan order was
counterbalanced so that half of the volunteers received
MDMA for the ﬁrst scan, and half received MDMA for the
second scan. ASL, arterial spin labeling; BOLD, blood
oxygen level–dependent.
Figure 2. Subjective effects of 3,4-methylenedioxy-
methamphetamine (MDMA). There were 29 items rated
4 hours after drug administration. Participants were
instructed to complete the items with reference to the
peak drug effects (where applicable). The items marked
with an asterisk were rated signiﬁcantly higher after
MDMA than placebo (p  .001, Bonferroni correction for
multiple comparisons). The mean ratings for 25 partici-
pants are shown plus the positive standard errors from
the mean (SE).
R.L. Carhart-Harris et al. BIOL PSYCHIATRY 2014;]:]]]–]]] 3of a greater spatial extent in the second ASL scan than the ﬁrst
(Supplement 1).
Correlations between CBF Effects and Subjective Ratings
Regions showing the most marked reductions in CBF after
MDMA administration included the visual cortex, thalamus, soma-
tosensory cortex, right hippocampus, and right amygdala. Correla-
tional analyses were restricted to these regions of interest. Masks
were derived from an anatomic atlas, and CBF changes in the
relevant regions were correlated with self-ratings of the intensity
of the subjective effects of MDMA. Signiﬁcant positive correlations
were observed between the magnitude of the CBF decreases in
the right amygdala (p ¼ .002) and right hippocampus (p ¼ .004)Figure 3. Decreases in cerebral blood ﬂow (CBF) after
administration of 3,4-methylenedioxymethamphetamine
(MDMA). (A) Regions of signiﬁcantly less CBF after
MDMA administration (scans 1 and 2) vs. placebo (scans
1 and 2) are displayed. These images are cluster-
corrected giving a whole-brain corrected statistical
threshold of p  .05. See Supplement 1 for additional
slices. (B, C) Decreased right amygdala and hippocampal
CBF predicts intense subjective effects after MDMA.
Values on the x-axis are ratings from the ﬁrst and second
arterial spin labeling scans after MDMA administration.
A corrected p value of  .005 was used. The decreases in
CBF after MDMA administration versus placebo increase
in magnitude from left to right. The greater the
decreases in CBF in the amygdalae and hippocampi
after MDMA administration, the more intense were the
drug’s subjective effects. ASL, arterial spin labeling; hipp,
hippocampus.after MDMA administration and the subjective intensity of the
drug effects (Figure 3B,C). Correcting for multiple comparisons
gave a revised statistical threshold of p  .005 (.05/10), and these
correlations survived this threshold. Because the amygdala and
hippocampus are limbic structures known to be involved in
affective processing, we also examined correlations between the
CBF changes and ratings of increased positive affect after MDMA
administration, and although correlations were in the predicted
direction, no signiﬁcant relationships were found.
RSFC Results
When vmPFC RSFC after MDMA administration was contrasted
against vmPFC RSFC after placebo administration, signiﬁcantwww.sobp.org/journal
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observed (cluster-corrected, z ¼ 2.3, p  .05; this threshold was
used for all of the RSFC analyses). Increases in vmPFC RSFC were
observed in visual cortex, both medially and laterally (left and
right hemispheres). Decreases were found in the midbrain
(including voxels in the vicinity of the dorsal raphe nuclei),
thalamus, amygdala, and posterior cingulate cortex (PCC).
When hippocampal RSFC after MDMA administration was
contrasted against hippocampal RSFC after placebo administra-
tion, signiﬁcant increases in RSFC were observed in the dorsal
ACC, right amygdala, and right middle frontal gyrus. Decreases
were found in the mPFC, left posterior parahippocampal/fusiform
gyrus, and left temporal cortex.
When amygdala RSFC after MDMA administration was contrasted
against amygdala RSFC after placebo administration, signiﬁcant
increases in RSFC were observed in the brainstem and bilaterally in
the anterior parahippocampal gyrus. Decreases in RSFC were found
in the cerebellum, left temporal cortex, medial orbitofrontal cortex,
and subgenual cingulate cortex. For images of positive RSFC to the
regions of interest during baseline conditions, see Supplement 1.
Relationship between Changes in RSFC and Subjective Effects
of MDMA
Six correlations were tested, giving a revised statistical threshold
of p  .008 (.05/6). Speciﬁcally, between-condition differences in
vmPFC-PCC, hippocampal-vmPFC, and amygdala-hippocampal RSFC
versus ratings of the intensity of the global subjective effects of
MDMA and ratings of positive mood were tested. There was a trend
toward decreased vmPFC-PCC RSFC after MDMA administration
correlating with intense (r ¼ .13, p ¼ .218) and positive (r ¼ .36, p ¼
.038) subjective effects, but neither correlation was signiﬁcant.
Similarly, there was a trend toward decreased hippocampal-vmPFC
RSFC after MDMA administration correlating with intense (r ¼ .32,
p ¼ .026) and positive (r ¼ .3, p ¼ .073) effects, but neither
correlation was signiﬁcant. Finally, there was a trend toward
increased amygdala-hippocampal RSFC correlating with intense
(r ¼ .382, p ¼ .01) and positive (r ¼ .159, p ¼ .225) subjective
effects, but these correlations were not signiﬁcant when corrected
for multiple testing.
Addressing Between-Condition Differences in Motion as a
Potential Confounder
All available methods were employed to control for subjective
motion in the RSFC analyses (e.g., motion parameter time courses and
outlier volumes were included as confounder variables in the ﬁrst-
level general linear models). In addition, between-condition motion in
the resting state BOLD scans was formally compared. There was
signiﬁcantly more movement in the MDMA than placebo scans (p ¼
.003); however, the magnitude of this difference was so small as to be
functionally insigniﬁcant (i.e., the mean relative movement per volume
in the RSFC scans was .072  .04 mm after placebo administration
and 0.099  .08 mm after MDMA administration. Mean motion failed
to explain any of the variance in the main RSFC outcomes when
tested in post hoc regression analyses containing the between-
condition differences in RSFC as the dependent variable and
between-condition differences in motion as a single explanatory
variable.
Addressing Between-Subject Differences in Drug Use as a
Potential Confounder
Because there was a large variability in previous drug use
among the study sample, additional regression analyses were run
to test for relationships between drug use and between-conditionwww.sobp.org/journaldifferences in RSFC. Speciﬁcally, using the same approach out-
lined previously, between-condition differences in RSFC were
entered as the dependent variable, and previous MDMA expo-
sure, recency of MDMA exposure, weekly alcohol use, and lifetime
cannabis use were entered separately as single explanatory
variables. Between-subject variance in drug use failed to explain
signiﬁcantly any of the between-condition RSFC outcomes.Discussion
This is the ﬁrst resting state fMRI study on the acute effects of
MDMA on spontaneous brain function. Decreased CBF was seen
in the amygdala and hippocampus, and this correlated with the
intensity of the drug’s effects. Decreases in vmPFC-MTL and
vmPFC-PCC RSFC and increase in amygdala-hippocampal RSFC
were also observed, and there were trend-level correlations
between these effects and the intensity and positive mood
effects of MDMA.
The CBF decreases after MDMA were localized to the sub-
calcarine visual cortex, pre–supplementary motor area, somato-
sensory cortex, superior frontal gyrus, midbrain and brainstem,
thalamus, hippocampus and parahippocampus, and amygdala.
The 5-HT1B receptor is especially densely expressed in the
subcalcarine domain of the visual cortex (28), which is precisely
where the CBF decreases in the visual cortex were observed. It is
natural to infer that endogenous 5-HT released by MDMA may
have stimulated this particular 5-HT receptor in this particular
region to produce the observed decreases in CBF. Supporting the
role of 5-HT in mediating this and the other main effects, MDMA
produces a 5-fold greater increase in synaptic 5-HT than dop-
amine (13), and dopamine and norepinephrine receptors are not
densely expressed in the visual cortex.
The decreases in CBF in the MTLs were one of the most
intriguing results of this study, particularly because the magnitude
of these decreases correlated positively with ratings of the drug’s
global subjective effects, even after correcting for multiple com-
parisons (Figure 3B,C). The MTL structures receive an especially
dense serotoninergic innervation (29), and 5-HT is found in higher
concentrations in the hippocampus than dopamine and norepi-
nephrine (30). The hippocampus (31) and amygdala (32) express
postsynaptic 5-HT1A receptors in high concentrations, endogenous
5-HT has a relatively high afﬁnity for 5-HT1A receptors (27), and the
effects of 5-HT stimulation of 5-HT1A receptors are hyperpolariza-
tion and a decrease in cell ﬁring rate (33). Other 5-HT receptors are
expressed in the hippocampus, amygdala, and parahippocampus
(e.g., the 5-HT7 receptor and 5-HT2A receptor (34,35)) but to a far
lesser extent than the 5-HT1A receptor (36). It is reasonable to infer
that the marked decreases in CBF in the MTLs were caused by an
effect of 5-HT on inhibitory postsynaptic 5-HT1A receptors.
Elevated limbic activity is a reliable characteristic of anxiety
states (37). Serotoninergic medications with anxiolytic properties,
such as selective serotonin reuptake inhibitors and 5-HT1A
receptor agonist buspirone, are thought to elicit their therapeutic
action via stimulation of inhibitory postsynaptic 5-HT1A receptors,
normalizing limbic activity (38). Acutely administered MDMA does
not appear to have typical anxiolytic properties in either animals
or humans (17,39); however, the subjective ratings displayed in
Figure 2 clearly demonstrate an increase in positive mood under
the inﬂuence of the drug (albeit without any effect on negative
mood—which was already low). Prosocial behaviors have pre-
viously been observed after MDMA administration (2,22,40), and
MDMA-induced prosocial behavior in rats was reduced after
R.L. Carhart-Harris et al. BIOL PSYCHIATRY 2014;]:]]]–]]] 5pretreatment with a selective 5-HT1A receptor antagonist (41).
Given the potent serotonin releasing properties of MDMA (1,13), it
can be inferred that the reduced MTL CBF observed here was
mediated by 5-HT1A receptor stimulation and is related, at least in
part, to the drug’s positive mood effects. However, contradicting
the role of 5-HT1A receptors in the mechanism of action of MDMA
is the ﬁnding that pretreatment with pindolol does not signiﬁ-
cantly attenuate the drug’s subjective effects (14,42); pindolol is a
partial agonist that may not provide effective blockade of
postsynaptic 5-HT1A receptors (43,44). Pretreatment studies with
potent and selective antagonists are required to elucidate the
speciﬁc receptor subtypes mediating the decreases in CBF.
Similar to the ASL outcomes, the RSFC analyses also yielded
robust results. For example, the decreases in vmPFC-PCC coupling
after MDMA administration are of interest given more recent
evidence that increased vmPFC-PCC coupling is positively asso-
ciated with rumination in depression (45). On this basis, we had
predicted that the decreases in vmPFC-PCC RSFC would correlate
with the drug’s positive mood effects, but although there was a
trend in this direction, it was not signiﬁcant after correction ormultiple comparisons. Decreased vmPFC-PCC RSFC has also been
found with psilocybin (21), a nonselective 5-HT2A receptor agonist
with potent consciousness-altering properties. Psilocybin produ-
ces an unconstrained style of cognition that is the inverse of the
constrained, ruminative style of thinking that is characteristic of
depression. Participants described a similar liberation of cognition
and imagination after MDMA administration (Figure 2), and
vmPFC-PCC coupling was decreased after administration of the
drug. In future research with MDMA, it would be interesting to
incorporate pretreatment with a selective 5-HT2A receptor antag-
onist to test the involvement of this speciﬁc receptor in mediating
the drug’s effects. The 5-HT2A receptor is highly expressed in both
the mPFC and PCC (46), and 5-HT2A receptor blockade was found
to signiﬁcantly attenuate the positive mood effects of both
MDMA (14) and psilocybin (47).
Regarding other circuitry implicated in the action of MDMA,
decreased mPFC-hippocampal RSFC was observed (Figure 4). The
uncinate fasciculus connects the vmPFC and MTL structures (48),
and other indirect connections (e.g., via the retrosplenial
cortex and ventral PCC) likely account for the substantial baselineFigure 4. Effect of 3,4-methylenedioxymethampheta-
mine (MDMA) on resting state functional connectivity
(RSFC). (A) Changes in ventromedial prefrontal cortex
(vmPFC) RSFC. (B) Changes in hippocampal RSFC after
MDMA administration. (C) Changes in amygdala RSFC
after MDMA administration. Increases in RSFC are shown
in yellow-orange, and decreases in RSFC are shown in
blue. All seeds are shown in red. The blue lines on the
axial and sagittal slices on the far right indicate the
planar position of the preceding slices. All images were
cluster-corrected, z ¼ 2.3, p  .05.
www.sobp.org/journal
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Research in rodents has shown that the mPFC exerts a top-down
inhibitory inﬂuence on limbic activity (49), often observed in the
context of emotional control (50). These regions have also been
implicated in the pathophysiology of PTSD. For example, patients
with pronounced dissociative symptoms exhibit elevated mPFC and
reduced MTL responses to trauma-related cues (51) presumably as
a result of an exaggerated inﬂuence of the mPFC on the MTLs (52).
More recently, MDMA has begun to be formally investigated as an
adjunct to psychotherapy for PTSD (16,17). It is claimed that MDMA
aids patients’ ability to cope with the distress of recollecting their
trauma when required to do so in psychotherapy (16). Similar to
limbic hyperactivity, increased coupling between the mPFC and
hippocampus is a marker of anxiety states and appears to be
modulated by the 5-HT1A receptor (53). There was a trend-level
positive correlation between the magnitude of the decreases in
mPFC-hippocampal coupling after MDMA administration and rat-
ings of positive mood and intensity of the drug’s global effects.
Further work is required to investigate the hypothesis that the
positive mood effects of MDMA are mediated, at least in part, by
decreased mPFC-hippocampal and mPFC-PCC coupling.
Although many aspects of the RSFC results are interesting, we
have focused on the effects that were especially marked and are
related to relevant previous work. The ﬁnal effect given special
attention is the increased coupling between the amygdala and
the hippocampus after MDMA administration. The magnitude of
the increases in amygdala-hippocampal RSFC correlated at a near
signiﬁcant level with ratings of the intensity of the global effects
of MDMA. Decreased amygdala-hippocampal RSFC has been
found in patients with PTSD relative to combat veterans without
PTSD (54). The authors of the study speculated that the decrease
in amygdala-hippocampal RSFC may relate to an impaired ability
to contextualize affective information in PTSD. It is intriguing that
MDMA had an inverse effect on amygdala-hippocampal RSFC in
the present study, increasing it in a manner that correlated with
the drug’s global subjective effects (albeit at a trend level).
Further work is required test both the safety and efﬁcacy of
MDMA in PTSD and the speciﬁc mechanisms by which it may be
effective. There is only preliminary evidence from a single
published pilot study to support the therapeutic potential of
MDMA in the treatment of PTSD (17). However, the results of the
present study indicate that the MTLs may be speciﬁcally impli-
cated in any potential therapeutic action of the drug.
There have been no previous resting state fMRI studies on
MDMA, but a steady-state positron emission tomography study
measured CBF after administration of 119 mg/70 kg MDMA in 16
healthy volunteers (9). Because the experimental conditions
differed from the conditions of the present study (e.g., partic-
ipants performed a low-level cognitive task during many of the
scans), it is difﬁcult to compare the study outcomes. Some
decreases in CBF were observed in the thalamus, amygdala,
and somatosensory cortex in the positron emission tomography
study, but increases in CBF (in the orbitofrontal cortex, visual
cortex, and cerebellum) were also observed. In another positron
emission tomography study of a proserotoninergic agent, intra-
venous fenﬂuramine was administered during steady-state cog-
nition, and increased frontal cortical and decreased thalamic CBF
was observed (55).
The present study is the largest and most advanced acute
MDMA human imaging study to date; however, it has some
important limitations. We did not incorporate retrospective
correction of physiological motion effects to correct for the
physiologic variance (56). However, this process had a negligiblewww.sobp.org/journaleffect on the results when previously applied to psilocybin fMRI
data (21). Similarly, the breath-hold paradigm incorporated into
the psilocybin fMRI design to test for drug-vascular interactions
did not reveal any modulatory inﬂuence with this serotoninergic
agent. Nevertheless, given the hemodynamic nature of the ASL
and BOLD signals, it remains plausible that some of the observed
effects were caused by a direct vascular action of MDMA or
(released) serotonin, and the design would have beneﬁted from
the inclusion of RETROICOR or a breath-hold paradigm, or both.
However, contradicting a direct vascular action of the drug, the
observed CBF and RSFC effects were localized to functionally
meaningful brain regions (e.g., the MTLs) rather than being global
in extent or proximal to regions with a high vascular input, and
the decreases in MTL CBF correlated with global subjective effects
of MDMA.
Five of the 25 participants in this study were ﬁlmed as part of a
television documentary on the effects of MDMA. These 5
participants were not ﬁlmed during scanning and completed
the study protocol in the same way as the other 20 participants.
However, to address concerns about ﬁlming being a potential
confounding variable, we reanalyzed the ASL data after removing
the ﬁve ﬁlmed participants, and the main effects of MDMA were
unchanged (Supplement 1).
A deﬁnite limitation of this study was the lack of a pharmaco-
logic pretreatment component. Several pretreatment studies with
MDMA in humans have now been published (14,42,57–66), and
an advanced design would have included an antagonist pretreat-
ment component to elucidate the pharmacologic mechanism
underlying the fMRI-measured effects of MDMA.
The hypothesis-driven nature of our seed-based RSFC analyses
could also be questioned. Seed-based RSFC requires prior
selection of speciﬁc seeds, and if prior hypotheses about the
functional importance of the chosen seeds are tenuous or lacking,
this selection process can seem arbitrary. However, the selection
of MTL seeds and the vmPFC in the present study can be justiﬁed
given their association with social and affective processing (67,68)
and the recognized modulatory inﬂuence of MDMA on these
functions (6,22,69). Nonetheless, other regions of interest could
have been selected if informed by speciﬁc prior hypotheses. In
contrast to seed-based RSFC, independent components analysis
is a data-driven technique that could have been applied to the
present data to identify resting state networks, which could have
been scrutinized in between-condition analyses, either looking at
between-network RSFC between conditions or differences in
RSFC within the independent components analysis–deﬁned net-
works. Relevant independent components analysis–based analy-
ses are the focus of a separate publication.
It would be misleading to infer that changes in RSFC between
a seed and other regions in the brain apply exclusively to the
selected seed. Indeed, the same between-condition differences in
RSFC may be shared by multiple regions. Related to this, RSFC
analyses do not provide information on the causal source of
changes in RSFC, and to address such questions one needs to
consider exploring effective-connectivity measures (70).
Another potential limitation of the study was the inclusion of
behavioral paradigms between the ﬁrst and second pair of resting
state scans. It is possible that these had carry-over effects on the
CBF and RSFC outcomes of the second pair of scans. However,
this possibility seems unlikely given that the outcomes of the
second ASL and BOLD resting state scans were consistent with
those of the ﬁrst pair (Supplement 1).
Finally, the effectiveness of the blinding procedure is compro-
mised when studying the acute effects of a relatively potent
R.L. Carhart-Harris et al. BIOL PSYCHIATRY 2014;]:]]]–]]] 7psychoactive drug such as MDMA. Participants correctly identiﬁed
when they had received MDMA or placebo in 45 of the 50 study
days, and the research team predicted correctly in 48 of the study
days. It is difﬁcult to circumvent this issue. A very low dose of
MDMA or another stimulant such as amphetamine could have
been added as a control condition. However, a drug-free baseline
is required to properly determine the effects of an experimental
compound. With this said however, the ineffectiveness of blind-
ing needs to be highlighted as a study limitation.
In conclusion, this is the ﬁrst study to have used resting state
fMRI to address the question of how MDMA works on the human
brain to produce its characteristic subjective effects. The results
revealed decreased CBF in MTL regions, decreased RSFC between
the vmPFC and PCC, decreased mPFC-hippocampus RSFC, and
increased amygdala-hippocampus RSFC. Taken together, the MTL
regions appear to be speciﬁcally implicated in the mechanism of
action of MDMA. However, these results should be seen as
informative rather than conﬁrmatory, and further research is
required to elucidate the precise mechanisms by which the
characteristic subjective effects of MDMA arise from its modu-
lation of brain activity.
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